Related Experiment Video
Updated: Aug 6, 2026
11:44
Surface Enhanced Raman Spectroscopy Detection of Biomolecules Using EBL Fabricated Nanostructured Substrates
Published on: March 20, 2015
Implementing surface plasmon resonance biosensors in drug discovery
1Center for Biomolecular Interaction Analysis University of Utah, School of Medicine 4A417, 50 North Medical Drive, 84132, Salt Lake City, UT, USA
Pharmaceutical Science & Technology Today
|September 21, 2000
Summary
Surface Plasmon Resonance (SPR) biosensors are advancing small-molecule drug discovery. This label-free technology offers real-time binding analysis for lead optimization and ADME studies, enhancing pharmaceutical development.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Pharmacology
Background:
- Surface Plasmon Resonance (SPR) biosensor technology has seen significant advancements.
- These improvements enhance its utility in pharmaceutical research and development.
Purpose of the Study:
- To highlight the application of SPR biosensors in small-molecule drug discovery.
- To discuss the advantages and emerging roles of SPR in pharmaceutical R&D.
Main Methods:
- Utilizing SPR biosensors for real-time binding analysis.
- Employing label-free detection methods.
- Conducting high-throughput screening (100-400 assays/day).
Main Results:
- SPR enables real-time kinetic data collection for compound-target interactions.
- The technology is suitable for lead optimization and secondary screening.
- Emerging applications include ADME (adsorption, distribution, metabolism, excretion) and proteomics.
Conclusions:
- SPR biosensors are valuable tools for small-molecule drug discovery and development.
- Their label-free, real-time capabilities offer significant advantages.
- SPR is positioned to play a major role in the future of the pharmaceutical industry.
